中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

695 records (took 0.034 seconds)

    RETENTIVE DEVICES FOR GASTROINTESTINAL TRACT
    1.
    发明申请
    RETENTIVE DEVICES FOR GASTROINTESTINAL TRACT 审中-公开

    公开(公告)号：WO2022185220A1

    公开(公告)日：2022-09-09

    申请号：PCT/IB2022/051815

    申请日：2022-03-02

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD.

    Inventor： BEN MENACHEM, Avshalom ,  ZALIT, Ilan

    IPC: A61M31/00 ,  A61K9/00 ,  A61B5/00

    Abstract: The present disclosure provides with a device (1000) for temporary residence at a predetermined location of the gastrointestinal tract of a subject, the device being configured to transfer from a closed configuration into an expanded configuration. The device is configured to be retained at said predetermined location of the subject. The device is further configured to transfer from the expanded configuration into an emptying configuration in which the device is configured to move past the predetermined location. This enables localized medical methods in the gastrointestinal tract of the subject.

    METHOD OF USING IL-27 AS A PREDICTIVE BIOMARKER OF CLINICAL RESPONSE TO GLATIRAMER ACETATE THERAPY
    3.
    发明申请
    METHOD OF USING IL-27 AS A PREDICTIVE BIOMARKER OF CLINICAL RESPONSE TO GLATIRAMER ACETATE THERAPY 审中-公开
    使用IL-27作为临床反应的预测性生物标记物的方法用于GLATIRAMER ACETATE治疗

    公开(公告)号：WO2017100199A1

    公开(公告)日：2017-06-15

    申请号：PCT/US2016/065175

    申请日：2016-12-06

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD. ,  ITO, Kouichi ,  DHIB-JALBUT, Suhayl

    Inventor： ITO, Kouichi ,  DHIB-JALBUT, Suhayl

    IPC: A61K38/03 ,  C07K4/00 ,  G01N33/50

    CPC classification number: G01N33/6869 ,  A61K38/02 ,  G01N2333/54 ,  G01N2333/5428 ,  G01N2800/285

    Abstract: The present invention provides a method for treating a subject afflicted with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: a) administering a therapeutic amount of the pharmaceutical composition to the subject; b) determining whether the subject is a glatiramer acetate responder by evaluating IL-27 concentration in the blood of the subject; and c) continuing the administration of the pharmaceutical composition if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is not identified as a glatiramer acetate responder.

    Abstract translation: 本发明提供了用包含醋酸格拉替雷和药学上可接受的载体的药物组合物治疗患有多发性硬化症的受试者的方法，其包括以下步骤：a）将治疗量的药物组合物 对象; b）通过评估受试者血液中的IL-27浓度来确定受试者是否是醋酸格拉替雷应答者; 和c）如果受试者被鉴定为醋酸格拉替雷应答者，则继续施用药物组合物，或者如果受试者未被鉴定为醋酸格拉替雷应答者，则改变受试者的治疗。

    USE OF LAQUINIMOD TO TREAT TRAUMATIC BRAIN INJURY
    5.
    发明申请
    USE OF LAQUINIMOD TO TREAT TRAUMATIC BRAIN INJURY 审中-公开
    使用LAQUINIMOD治疗TRAUMATIC脑损伤

    公开(公告)号：WO2017027512A1

    公开(公告)日：2017-02-16

    申请号：PCT/US2016/046169

    申请日：2016-08-09

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  LAMB, Bruce ,  KATSUMOTO, Atsuko

    Inventor： LAMB, Bruce ,  KATSUMOTO, Atsuko

    IPC: A61K31/47 ,  A61K31/4704 ,  C07D215/56 ,  C07D215/227

    CPC classification number: A61K31/4704 ,  A61K45/06 ,  C07D215/227 ,  C07D215/56

    Abstract: This application provides for a method of treating a subject suffering from traumatic brain injury, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application also provides use of laquinimod in the manufacture of a medicament for treating a subject suffering from traumatic brain injury. This application also provides laquinimod for use in treating a subject suffering from traumatic brain injury. This application also provides use of laquinimod in treating a subject suffering from traumatic brain injury. This application also provides a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from traumatic brain injury. This application also provides a pharmaceutical oral unit dosage form of laquinimod for use in treating a subject suffering from traumatic brain injury.

    Abstract translation: 本申请提供了治疗患有创伤性脑损伤的受试者的方法，该方法包括向受试者定期施用一定量的有效治疗受试者的拉喹莫德或其药学上可接受的盐。 本申请还提供了拉喹莫德在制备用于治疗患有创伤性脑损伤的受试者的药物中的用途。 本申请还提供了用于治疗患有创伤性脑损伤的受试者的拉喹莫德。 本申请还提供了使用拉喹莫德治疗患有创伤性脑损伤的受试者。 本申请还提供了包含用于治疗患有创伤性脑损伤的受试者的拉喹莫德的药物组合物。 本申请还提供了用于治疗患有创伤性脑损伤的受试者的拉喹莫德的药物口服单位剂量形式。

    PROCESS FOR MANUFACTURING GLATIRAMER ACETATE PRODUCT
    7.
    发明申请
    PROCESS FOR MANUFACTURING GLATIRAMER ACETATE PRODUCT 审中-公开
    制备玻璃酸乙酯产品的方法

    公开(公告)号：WO2016122722A1

    公开(公告)日：2016-08-04

    申请号：PCT/US2015/051203

    申请日：2015-09-21

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  COHEN, Rakefet ,  HABBAH, Sasson ,  SAFADI, Muhammad

    Inventor： COHEN, Rakefet ,  HABBAH, Sasson ,  SAFADI, Muhammad

    IPC: A61K38/02

    CPC classification number: A61K38/02 ,  A61K9/0019 ,  A61K9/08 ,  A61K38/03 ,  A61K38/16 ,  A61K47/26

    Abstract: The patent provides a process of preparing a pharmaceutical preparation of glatiramer acetate and mannitol in a suitable container comprising the steps of: (i) obtaining an aqueous pharmaceutical solution of glatiramer acetate and mannitol; (ii) filtering the aqueous pharmaceutical solution at a temperature of from above 0°C up to 17.5°C to produce a filtrate; and (iii) filling the suitable container with the filtrate obtained after performing step (ii), so as to thereby prepare the pharmaceutical preparation of glatiramer acetate and mannitol in the suitable container. This patent further provides an aqueous pharmaceutical solution comprising 40mg/ml glatiramer acetate and 40mg/ml mannitol, wherein the aqueous pharmaceutical solution a) has a viscosity in the range of 2.0-3.5 cPa; or b) has an osmolality in the range of 275-325 mosmol/Kg. This patent also provides a prefilled syringe, an automated injector and a method of treatment of a human patient.

    Abstract translation: 该专利提供了在合适的容器中制备乙酸格拉默和甘露糖醇的药物制剂的方法，包括以下步骤：（i）获得乙酸格拉默和甘露醇的药物水溶液; （ii）在高于0℃至17.5℃的温度下过滤药物水溶液以产生滤液; 和（iii）在进行步骤（ii）之后用所得滤液填充合适的容器，从而在合适的容器中制备乙酸格拉默和甘露糖醇的药物制剂。 该专利还提供了包含40mg / ml醋酸格拉默和40mg / ml甘露醇的药物水溶液，其中药物水溶液a）的粘度范围为2.0-3.5cPa; 或b）的重量摩尔渗透压浓度范围为275-325 mosmol / Kg。 该专利还提供预充式注射器，自动注射器和治疗人类患者的方法。

    ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE
    8.
    发明申请
    ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE 审中-公开

    公开(公告)号：WO2016003919A8

    公开(公告)日：2016-01-07

    申请号：PCT/US2015/038349

    申请日：2015-06-29

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  SCHMIDT, Malle ,  PÄRI, Malle ,  LAOS, Marit ,  MAASALU, Ants ,  KALJUSTE, Kalle

    Inventor： SCHMIDT, Malle ,  PÄRI, Malle ,  LAOS, Marit ,  MAASALU, Ants ,  KALJUSTE, Kalle

    IPC: A61K31/451

    Abstract: This invention provides an isolated compound having the structure: The invention also provides for a process for preparing 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-4-ol, 1-(3,3-bis(3-(methylsulfonyl)phenyl)propyl)-4-(3-(methylsulfonyl) phenyl)piperidone, 1,4-bis((3-(1 -propylpiperidin-4-yl)phenyl)sulfonyl)butane, (3R,4S)-4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-3-ol, 4-(3-(methylsulfonyl)phenyl)-l-propylpiperidine 1- oxide, 1-(2-methylpentyl)-4-(3-(methylsulfonyl)phenyl)piperidine, 4-(3-(methylsulfinyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine, and 4-(3-(methylsulfonyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine. This invention also provides an impurity or a salt thereof for use, as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof. This invention further provides a process for producing a pridopidine drug product comprising obtaining a pridopidine drug substance and mixing the pridopidine drug substance with suitable excipients so as to produce the pridopidine drug product. This invention also provides a process for producing a pridopidine drug product. This invention also provides a process of distributing a pridopidine drug product.

    ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE
    9.
    发明申请
    ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE 审中-公开
    孕激素类似物，其制备和使用

    公开(公告)号：WO2016003919A1

    公开(公告)日：2016-01-07

    申请号：PCT/US2015/038349

    申请日：2015-06-29

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  SCHMIDT, Malle ,  PÄRI, Malle ,  LAOS, Marit ,  MAASALU, Ants ,  KALJUSTE, Kalle

    Inventor： SCHMIDT, Malle ,  PÄRI, Malle ,  LAOS, Marit ,  MAASALU, Ants ,  KALJUSTE, Kalle

    IPC: A61K31/451

    CPC classification number: A61K31/451 ,  C07D211/24 ,  C07D211/42 ,  C07D211/52 ,  G01N30/88 ,  G01N2030/8872

    Abstract: This invention provides an isolated compound having the structure: The invention also provides for a process for preparing 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-4-ol, 1-(3,3-bis(3-(methylsulfonyl)phenyl)propyl)-4-(3-(methylsulfonyl) phenyl)piperidone, 1,4-bis((3-(1 -propylpiperidin-4-yl)phenyl)sulfonyl)butane, (3R,4S)-4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-3-ol, 4-(3-(methylsulfonyl)phenyl)-l-propylpiperidine 1- oxide, 1-(2-methylpentyl)-4-(3-(methylsulfonyl)phenyl)piperidine, 4-(3-(methylsulfinyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine, and 4-(3-(methylsulfonyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine. This invention also provides an impurity or a salt thereof for use, as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof. This invention further provides a process for producing a pridopidine drug product comprising obtaining a pridopidine drug substance and mixing the pridopidine drug substance with suitable excipients so as to produce the pridopidine drug product. This invention also provides a process for producing a pridopidine drug product. This invention also provides a process of distributing a pridopidine drug product.

    Abstract translation: 本发明提供具有以下结构的分离的化合物：本发明还提供了制备4-（3-（甲基磺酰基）苯基）-1-丙基哌啶-4-醇，1-（3,3-双（3-（ 甲基磺酰基）苯基）丙基）-4-（3-（甲基磺酰基）苯基）哌啶酮，1,4-双（（3-（1-丙基哌啶-4-基）苯基）磺酰基）丁烷，（3R，4S） - （3-（甲基磺酰基）苯基）-1-丙基哌啶-3-醇，4-（3-（甲基磺酰基）苯基）-1-丙基哌啶1-氧化物，1-（2-甲基戊基）-4-（3- 甲基磺酰基）苯基）哌啶，4-（3-（甲基亚磺酰基）苯基）-1-丙基-1,2,3,6-四氢吡啶和4-（3-（甲基磺酰基）苯基）-1-丙基-1,2 ，3,6四氢吡啶。 本发明还提供了一种杂质或其盐作为用于检测药物组合物中微量杂质的参考标准，其包含派多啶或其药学上可接受的盐。 本发明进一步提供了一种制备哌多啶药物产品的方法，包括获得一种派多凡定药物，并将该丙泊德吡啶药物与合适的赋形剂混合，从而产生格列方啶药物。 本发明还提供了制备格列方啶药物的方法。 本发明还提供了分布丙泊德苷药物的方法。

    TREATMENT OF CROHN'S DISEASE WITH DELAYED-RELEASE 6-MERCAPTOPURINE
    10.
    发明申请
    TREATMENT OF CROHN'S DISEASE WITH DELAYED-RELEASE 6-MERCAPTOPURINE 审中-公开
    用延迟释放6-MERCAPTOPURINE治疗高血糖病

    公开(公告)号：WO2015168448A1

    公开(公告)日：2015-11-05

    申请号：PCT/US2015/028590

    申请日：2015-04-30

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  KOLATCH, Brenda ,  HOTOVELY-SALOMON, Anna

    Inventor： KOLATCH, Brenda ,  HOTOVELY-SALOMON, Anna

    IPC: A61K9/28 ,  A61K31/52

    CPC classification number: A61K31/52 ,  A61K9/0053 ,  A61K31/573 ,  A61K31/58 ,  A61K31/606 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods of treating patients suffering from Crohn's disease or ulcerative colitis who did not experience a clinical response to previous thiopurine administration, or suffered side effects from previous thiopurine administration, by administering a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed. Methods of treating patients suffering from Crohn's disease or ulcerative colitis who are also being administered a steroid, 5-aminosalicylic acid, or an antibiotic by adjunctively administering a delayed release pharmaceutical composition comprising 6- mercaptopurine are also disclosed.

    Abstract translation: 公开了通过施用包含6-巯基嘌呤的延迟释放药物组合物治疗患有克罗恩病或溃疡性结肠炎的患者的方法，所述患者没有经历对先前的硫嘌呤给药的临床反应或遭受以前的硫嘌呤给药的副作用。 还公开了通过辅助施用包含6-巯基嘌呤的延迟释放药物组合物来治疗也被给予类固醇，5-氨基水杨酸或抗生素的患有克罗恩病或溃疡性结肠炎的患者的方法。

Patent Agency Ranking